Peroxisome
proliferator-activated receptor gamma (PPARc) agonists demonstrate antitumor activity likely through transactivating genes that regulate cell proliferation, apoptosis, and differentiation. The PAX8/PPARc fusion oncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative suppression of wild-type PPARc, suggesting that it may be a tumor suppressor gene in thyroid cells. We have identified a novel high-affinity PPARc agonist (RS5444) that is dependent upon PPARc for its biological activity. This is the first report of this molecule and its antitumor activity. In vitro, the IC 50 for growth inhibition is B0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited threeto fourfold in nude mice. siRNA against PPARc and a pharmacological antagonist demonstrated that functional PPARc was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21 WAF1/CIP1 . Silencing p21 WAF1/CIP1 rendered cells insensitive to RS5444. RS5444 plus paclitaxel demonstrated additive antiproliferative activity in cell culture and minimal ATC tumor growth in vivo. RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel. Our data indicate that functional PPARc is a molecular target for therapy in ATC.
Introduction
Peroxisome proliferator-activated receptor gamma (PPARg) agonists that include synthetic and naturally occurring compounds, such as thiazolidinediones (Tzds), amino-acid derivatives, prostaglandins, and fatty acid metabolites have demonstrated chemopreventive and antitumor activity against a variety of human cancers in cell culture, animal models, and clinical trials (reviewed in Rosen and Spiegelman, 2001; Girnun and Spiegelman, 2003; Koeffler, 2003) . However, they have been used with little or limited success in Phase I clinical trials, potentially due to issues related to end stage disease. The common trait that is attributed to the antitumor activity of these divergent classes of compounds such as nonsteroidal anti-inflammatory drugs (NSAIDs), amino-acid derivatives (e.g. GW7845), polyunsaturated fatty acids and eicosanoids (reviewed in Debril et al., 2001) , and thiazolidinediones is attributed to the binding and activation of PPARg (reviewed in Fujiwara and Horikoshi, 2002; YkiJarvinen, 2004) . These findings are in keeping with the suggestion that PPARg acts as a tumor suppressor gene (Nakajima et al., 2001; Smith et al., 2001; Koeffler, 2003) . Mechanisms of PPARg-mediated antitumor activity by Tzds demonstrated experimentally include induction of cellular differentiation (Elstner et al., 1998; Guan et al., 1999; Kitamura et al., 1999; Chang and Szabo, 2002; Kawa et al., 2002) , promotion of cell cycle arrest (Brockman et al., 1998; Kitamura et al., 1999; Motomura et al., 2000; Itami et al., 2001; Koga et al., 2001; Nakashiro et al., 2001; Takashima et al., 2001; Yin et al., 2001; Kawa et al., 2002; Hong et al., 2004; Rumi et al., 2004; Chen and Harrison, 2005) , antiangiogenic effects (reviewed in Alarcon de la Lastra et al., 2004) and induction of apoptosis (Elstner et al., 1998; Kubota et al., 1998; Chang and Szabo, 2000; Tsubouchi et al., 2000; Eibl et al., 2001; Takashima et al., 2001; Yang and Frucht, 2001; Lovekamp-Swan and Chaffin, 2005; Yuan et al., 2005) .
A common mutation in follicular thyroid tumors occurs in PAX8/ PPARg rearrangement, resulting in a putative downregulation of the wild-type PPARg activity via a dominant negative mechanism (Kroll et al., 2000; Dwight et al., 2003; Gregory et al., 2004; McIver et al., 2004; Lui et al., 2005) . This suggested that PPARg may act as a tumor suppressor gene (Kroll et al., 2000; Lui et al., 2005) . This mutation has not been identified in the more frequent occurring papillary carcinoma (B80% of all thyroid cancers) or the rarer, but deadly anaplastic thyroid carcinoma (ATC). While effective therapies for papillary and follicular thyroid carcinomas exist, there is little or no effective therapy for patients diagnosed with ATC with a mortality near 100% (reviewed in Sherman, 2003) . Over 90% of patients with ATC are older than 50 years and almost 70% are women. They present with widespread local invasion and often with metastases to lungs, pleura, bone, and/or brain. Paclitaxel has been found to be effective in preclinical models (Ain et al., 1996) , and its efficacy in a clinical trial led to its use for ATC (Ain et al., 2000) . Our work is focused upon identifying compounds with antitumor activity against ATC and then to identify which of these in combination are most effective as chemotherapeutic agents. One of these agents is a novel PPARg agonist in which we have explored its antitumor activity and mechanism of action in human ATC cells in vitro and in vivo. When combined, paclitaxel and RS5444 acted additively to inhibit cell proliferation and tumor growth in vitro and in vivo.
Results
Binding affinity of RS5444 correlates with growth inhibition Ligand binding to the heterodimeric PPARg:RXR complex leads to functional transcriptional responses in ATC cells. Expression of PPARg and RXRa was demonstrated in three representative human ATC cell lines (Figure 1a) . We examined 12 human ATC cell lines and all express nuclear PPARg (data not shown).
Immunocytochemistry (ICC) also demonstrated that PPARg was present predominantly in the nucleus (Figure 1b) . A 10 nM dose of RS5444 activates PPARg:RXRa-dependent transcription as demonstrated in a transient transfection assay utilizing a PPRE response element fused to a luciferase reporter gene (PPRE3-tk-luc; Figure 1c ). DRO cells were treated in culture with RS5444, rosiglitazone, or troglitazone at the indicated concentrations (Figure 2a and B). DRO cells were transiently transfected with PPRE3-tk-luc to examine effective concentrations at which 50% maximal transcriptional response (EC 50 ) occurs (Figure 2a ). The EC 50 s are B1 nM (RS5444), B65 nM (rosiglitazone) and B631 nM (troglitazone). Similarly, the calculated inhibitory concentration at which 50% of cell proliferation is inhibited (IC 50 ) is B0.8 nM for RS5444, B75 nM for rosiglitazone, and B1412 nM for troglitazone ( Figure 2b ). The EC 50 concentrations match closely to the IC 50 concentrations for each compound (Figure 2b ). This suggests that all three Tzds act via PPARg for their growth inhibitory effects upon DRO cells in culture. RS5444 specifically activates PPARg, but not PPARa or cine) . We also examined the ability of RS5444 to inhibit clonogenic growth of DRO cells in soft agar (Figure 2c ). Inhibition is dose responsive with inhibition of 63% at 1 nM, 98% at 10 nM, and 99.4% at 100 nM RS5444 (Figure 2c ). Thus, we demonstrated that RS5444 activates PPARg at subnanomolar concentrations and that these concentrations match those used to inhibit cell proliferation. We also show that multiple ATC cell lines possess transcriptionally functional PPARg complexes.
PPARg is requisite for RS5444 to inhibit cell proliferation To establish the dependence of the RS5444-induced effects on PPARg, we inhibited its expression using siRNA approaches. Scrambled siRNA left lane (À) and siRNA against PPARg right lane ( þ ) transfected into DRO ( Figure 3a ) and ARO cells (data not shown) selectively abolished the expression of PPARg protein with no effect upon RXRa expression. In the presence of PPARg siRNA, cells challenged by 10 nM RS5444 no longer upregulate PPRE3-tk-luc activity (Figure 3b ). Complete loss of protein expression occurred at 72 and 96 h (data not shown). We also used a pharmacological approach to test the role of PPARg in Tzd regulated transcription. Using similar micromolar concentrations and conditions as cited in published reports for the irreversible PPARg antagonist, GW9662 (Perez-Ortiz et al., 2004; Rumi et al., 2004; Turturro et al., 2004) , a complete blockade of PPARg mediated luciferase transcription was demonstrated for all three Tzds (Figure 3c ). Thus, using a siRNA and a pharmacological approach, transcription mediated by functional PPARg was completely blocked. We next tested the role of PPARg in mediating the ability of Tzds to inhibit cell proliferation using GW9662. Treating cells with 10 mM GW9662 had no significant effect upon cell proliferation compared to that of control ( Figure 3d , lane 1/Ctrl vs lane 2/10 mM GW9662). However, when cells were pretreated for 5 min with 10 mM GW9662 and then treated with 10 nM RS5444, inhibition of cell proliferation by RS5444 was completely blocked (Figure 3c , lanes 3 vs 4 and 2). Inhibition of cell proliferation by rosiglitazone (Figure 3c , lanes 5 vs 6 and 2) and troglitazone ( Figure 3c , lanes 7 vs 8 and 2) was also attenuated by GW9662 demonstrating that PPARg mediates inhibition of cell proliferation. It should be noted that in the presence of GW9662, 97% of cell proliferation was reversed for RS5444 while 69.5% for rosiglitazone and 56.5% for troglitzaone. Thus, functional PPARg is required for RS5444 as well as other Tzds to inhibit cell proliferation in human ATC cells in culture. Cells were treated every 48 h as described in Materials and methods over 6 days. Cell numbers were counted and data were plotted as mean values7s.d. IC 50 values were calculated to be: RS5444 B0.8 nM, rosiglitazone B75 nM, and troglitazone B1.4 mM. (c) DRO cells were plated in triplicate on soft agar for colony formation and treated with the indicated doses of RS5444. Colonies were stained and counted after 2 weeks. *Po0.01, when treatment was compared to control.
RS5444 inhibits ATC tumor growth and angiogenesis in an animal tumor model but does not induce apoptosis We next tested RS5444 in vivo for its ability to block tumor establishment (pretreat animals with RS5444 for 1 week followed by 1 million cells injected ectopically) as well as tumor growth and regression (establish tumor for 1 week followed by RS5444 treatment). When RS5444 was administered in the diet to athymic nude mice prior to DRO tumor cell implantation, tumor growth was inhibited in a dose responsive fashion. At the highest dose, 0.025% RS5444 inhibited growth on day 32 by 94.4% as compared to that of control ( Figure 4a ). In this treatment group, five of 10 animals did not develop demonstrable tumors. In the 0.0025% treatment group, tumor growth was inhibited by 62.3% compared to that of control on day 32 while the 0.00025% dose demonstrated no growth inhibitory activity as compared to control (Figure 4a ). We next allowed tumors to establish in the mouse and began 0.025% RS5444 treatment of mice 1 week after DRO Tzds have demonstrated antiangiogenic properties thus prompting us to examine this in tumor tissues treated with RS5444 (reviewed in (Panigrahy et al., 2003; Alarcon de la Lastra et al., 2004) ). DRO tumors removed on day 35 of control and 0.025% RS5444 treated mice were probed for expression of PCNA, a molecular marker for proliferation using immunohistochemical (IHC) techniques. PCNA levels were downregulated 41.9% in DRO tumors exposed to RS5444 (6.171.1) as compared to controls (10.571.3). CD31, an endothelium specific protein marker for angiogenesis was also examined in these tumors by IHC. Cells were transfected with siRNA for 72 h followed by PPRE3-tk-luc reporter transfection and treatment with 10 nM RS5444 for 24 h. PPRE3-tk-luc transfected cells (24 h) that were treated with 10 mM GW9662 followed by 10 nM RS5444 1 h later demonstrated complete loss of RS5444 inducible luciferase activity. Cotransfection with renilla luciferase allowed for normalization to relative light units (RLU). (c) PPRE3-tk-luc transfected DRO cells pretreated for 5 min with 10 mM GW9662 prior to 10 nM RS5444, 1 mM rosiglitazone, or 10 mM troglitazone no longer activate PPARg-induced luciferase activity. (d) DRO cells pretreated for 1 h with 10 mM GW9662 prior to 10 nM RS5444, 1 mM rosiglitazone, or 10 mM troglitazone are no longer growth inhibited demonstrating that PPARg is essential for inhibition of cell proliferation by TZDs. DRO cells were treated with the indicated compounds every 48 h over 6 days. Cell numbers were counted and data were plotted as mean values7s.d. * indicates Po0.01, when treatment is compared to control and **indicates Po0.05 when GW9662/agonist is compared to GW9662 alone. values 7s.e. from individual mice in each group (n ¼ 8). Po0.05 when RS5444 treatment was compared to control.
RS5444 did not appear to induce apoptosis in ATC tumor tissue from nude mice ( Figure 5a ) and in culture ( Figure 5b ) as evidenced by the lack of poly-ADP ribosyl polymerase (PARP) cleavage and measurable activated caspase 3 activity. DRO cells in culture were exposed to 10 nM RS5444 for 1, 2, 4, or 6 days. Protein lysates were examined for full length PARP (116 kD) and cleaved PARP (85 kD). HeLa cells treated with 50 nM paclitaxel were used as a control for cleaved PARP (indicated by 'C' in Figure 5a and b). The cleaved PARP was clearly demonstrated in HeLa cells treated with paclitaxel but not in cells treated with 10 nM RS5444. Procaspase 3 was present in high levels but caspase 3 was not activated (Casp-3) in tumor tissues ( Figure 5a ) or cell culture ( Figure 5b ) when compared to the appropriate controls. b-Actin expression demonstrated that each lane was equally loaded. Note that there was some expression of Casp-3 at days 4 and 6 in cell culture, but it was not in response to RS5444.
RS5444 induces cyclin kinase inhibitors (CKI) in ATC cells
Since RS5444 inhibits cell proliferation and appears not to induce apoptosis, we next examined whether cyclin kinase inhibitors (CKIs) were upregulated and corresponding cyclins were downregulated ( Figure 6a ). RS5444 induced upregulation of cyclin kinase inhibitors (CKIs) in cell culture within 24 h of treatment ( Figure 6a ). In Figure 6a , DRO cells treated with 10 nM RS5444 demonstrated an upregulation of CKIs, p21 WAF1/CIP1 and p16, at 12 and 24 h. p27 Kip1 and p18 levels appeared unchanged (Figure 6a ). Cyclin D1 did not appear to change at 24 h after RS5444 treatment but cyclin E did decrease by 24 h. Based upon the alterations identified in cell culture, we examined p21 WAF1/CIP and p16 protein levels in ATC tumors in two ectopic athymic nude mouse models. Using DRO tumor tissues, 0.025% RS5444 induced p21 WAF1/CIP1 strongly and p16 in one instance (Figure 6b ). In ARO tumor tissues, a strong increase in p21 WAF1/CIP1 protein levels resulted in 0.025% treated animals while p16 did not appear to be expressed, at least under the conditions used for detection by Western analysis (Figure 6b ). Of the CKIs and cyclins, upregulation in p21 WAF1/CIP1 was consistent following RS5444 treatment in cell culture and tumor tissues from mice using two different ATC cell lines ( Figure 6 ).
PPARg is requisite for p21
WAF1/CIP1 upregulation and p21 WAF1/CIP1 mediates RS5444 antiproliferative effects in ATC cells To determine whether RS5444 activation of PPARg is necessary for upregulation of p21 WAF1/CIP1 protein levels, DRO cells were transfected with PPARg siRNA for 72 h followed by 10 nM RS5444 for 24 h (Figure 7a ). RS5444 in the presence of scrambled siRNA (negative control) enhanced p21 WAF1/CIP1 protein levels ( Figure 7a , panel 1 vs 2) but this effect was blocked in presence of PPARg siRNA (Figure 7a, panel 3 vs 2) . Phase contrast microscopy demonstrated the presence of near confluent cells treated with PPARg siRNA and RS5444 (Figure 7a , panels 1a to 4a). Again, using a pharmacological approach, 10 mM GW9662 combined with 10 nM RS5444 also blocked enhanced expression of p21 WAF1/CIP1 protein levels as analysed by ICC (Figure 7a , panel 4 vs 2). Thus, the ability of RS5444 to upregulate p21 WAF1/CIP1 protein levels is PPARg dependent. We next examined whether the upregulation of p21 WAF1/CIP1 protein was necessary for RS5444 to inhibit cell proliferation. We first demonstrated that siRNA directed against p21
specifically blocks the ability of RS5444 to upregulate p21 WAF1/CIP1 protein levels. DRO cells were pretreated with p21 WAF1/CIP1 siRNA for 24 h followed by stimulation with 10 nM RS5444. Under these conditions, upregulation of p21 WAF1/CIP1 protein levels were blocked ( Figure 7b , top row, siRNA 'À' vs ' þ '). Loss of p21 WAF1/CIP1 protein expression appears specific in that p27 Kip , PPARg, and RXRa levels are not altered in the presence of p21 WAF1/CIP1 siRNA ( Figure 7b ). We next demonstrated that blocking the upregulation of p21 WAF1/CIP1 with p21 WAF1/CIP1 siRNA prevented the ability of RS5444 to inhibit cell proliferation (Figure 7c ). RS5444 (10 nM) inhibited cell proliferation by 81.6%73.4 in cells pretreated with a scrambled siRNA compared to 28.9%72.4 in the presence of p21 WAF1/CIP1 siRNA. Note that cells were treated every 48 h with 10 nM RS5444 with pretreatment of either siRNA p21 WAF1/CIP1 or scrambled siRNA. It is possible that the siRNA p21
expression ( Figure 7b, top row) . None the less, activation of PPARg followed by upregulation of nuclear p21 WAF1/CIP1 appeared to be the major mechanism by which RS5444 induces cell proliferation arrest.
Combinatorial therapy induces enhanced antitumor activity Next, combinatorial therapy of RS5444 and paclitaxel was tested. The rationale for this is based upon a recent report demonstrating that p21 WAF1/CIP1 enhanced apoptosis induced by manumycin and paclitaxel in ATC cells (Yang et al., 2003) along with the efficacy demonstrated for paclitaxel in a clinical trial of ATC patients (Ain et al., 2000) . We reasoned that RS5444 strongly upregulated p21
WAF1/CIP1 and that increased p21 may lead to enhanced antitumor activity in the presence of paclitaxel. As shown in Figure 8a , different concentrations of RS5444 and paclitaxel were used in a cell proliferation assay to determine the concentration at which 25% inhibition of cell proliferation occurred (IC 25 ). The IC 25 for RS5444 was B0.05 nM and for paclitaxel was B0.3 nM as calculated from the dose response curves in Figure 8a . This allowed us to then combine the two agents at their IC 25 concentrations to determine whether they possessed additive, synergistic, or antagonist antiproliferative activity. The fractional inhibition method was used to determine synergism or additive effects. Synergism is defined as i 1,2 >i 1 þ i 2 and additivity is defined as i 1,2 ¼ i 1 þ i 2 where 'i' is defined as the percent inhibition of compound 1 (i 1 ) and compound 2 (i 2 ) alone or in combination (i 1,2 ). As shown in Figure 8b , adding the percent inhibition of each compound administered alone was 42.5% (17.971.6 þ 24.672.0), which was essentially the same (taking into consideration the s.d. for each) as 45.873.4% when paclitaxel and RS5444 were combined. This model indicated that the two compounds acted additively. We next tested these two agents alone or in combination in an animal model using DRO (Figure 8c ) and ARO cells (Figure 8d ). A total of 1 million ATC tumor cells were injected ectopically and allowed to establish tumors for a week followed by 0.025% RS5444 administered in the diet. Potent inhibition of tumor growth in DRO (Figure 8c (Figure 8c and d) . Note that in the RS5444 þ paclitaxel treated DRO group, two of 10 tumors regressed and completely disappeared.
It should be noted that upon autopsy, heart weights were increased in groups exposed to 0.025% RS5444. The heart weights normalized to body weights are as follows: Control ¼ 0.50870.052; 0.025% RS5444 ¼ 0.71670.073; paclitaxel ¼ 0.51570.075 and RS5444/ paclitaxel ¼ 0.69870.085. A statistically significant increase in heart weight of 41% in RS5444 and 37% in RS5444/paclitaxel occurred. We performed an experiment in which RS5444 was removed for 3 weeks, normalized heart weights for RS5444 (0.57570.034) returned to that of controls (0.49670.027). This finding is consistent with the toxicity profile of Tzds currently in use for treatment of type 2 diabetes (e.g. rosiglitazone, ciglitazone, and pioglitazone) demonstrates edema and risk of heart failure reported in 4-6% of patients compared with 1-2% of patients on placebo (reviewed in Yki-Jarvinen, 2004 ).
Enhanced induction of apoptosis by RS5444 in combination with paclitaxel is mediated via p21 WAF1/CIP1
We have demonstrated that RS5444 did not induce apoptosis by examining PARP degradation and caspase 3 activity (Figure 6 ). Owing to two reports in the literature (Yeung et al., 2000; Yang et al., 2003) and our observation that RS5444 enhanced p21 WAF1/CIP1 expression, we next examined the ability of RS5444 to enhance apoptosis in the presence of paclitaxel (Figure 9 ). Using two different methods, DAPI and TUNEL, to examine apoptosis, 10 nM RS5444 did not induce apoptosis in DRO (Figure 9a , Ctrl vs RS5444) and ARO (Figure 9b , Ctrl vs RS5444) cells but when RS5444 is combined with paclitaxel, apoptosis was doubled compared to apoptosis induced by paclitaxel alone (Figure 9a and b, paclitaxel vs RS/Pac). We next examined the role of p21 WAF1/CIP1 in the ability of RS5444 to enhance paclitaxel-induced apoptosis. Using p21 WAF1/CIP1 siRNA to silence p21
, we demonstrated that upregulation of p21 WAF1/CIP1 nuclear protein expression is necessary for RS5444 to enhance paclitaxel induced apoptosis in ATC cells (Figure 9c ). Scrambled or p21 WAF1/CIP1 siRNA alone did not affect apoptosis ( 
Discussion
This is the first report of RS5444, a novel Tzd with high affinity and specificity for PPARg transcriptional activation. In this report, we demonstrated antitumor activity against anaplastic thyroid carcinoma, a poorly differentiated and aggressive cancer that exhibits near 100% fatality within months of diagnosis. Comparing EC 50 biological activities for RS5444 to that of prior generations of Tzds such as rosiglitazone, a >50-fold diminution in the concentration was required for RS5444 to achieve the same biological activity (induction of PPRE3-tk-luc activity) and compared to troglitazone, the fold change was >750-fold. Interestingly, growth inhibitory activity did not necessarily correlate with PPARg activity. As noted in Figure 3d , RS5444, rosiglitazone and troglitazone demonstrated nearly identical growth inhibition in DRO cells at their maximal growth inhibitory concentrations (Figure 2b ) but differed sharply upon dependence of functional PPARg. In the presence of the PPARg antagonist, GW9662, RS5444 mediated inhibition of cell proliferation was almost completely abolished (B97%) while that of rosiglitazone was B70% and troglitazone was B57% abolished. This data suggested that these latter two compounds may be acting through a non-PPARgspecific mechanism (Castrillo et al., 2001; Palakurthi et al., 2001; Galli et al., 2004; Rumi et al., 2004; Huang et al., 2005) . At nanomolar concentrations, the ability of RS5444 to antagonize cell proliferation in ATC cells was absolutely dependent upon the presence of functional PPARg as shown by the ability of PPARg siRNA and GW9662 to inhibit cell growth. Our study is one of few that clearly documents PPARg-mediated growth inhibitory effects of a Tzd (Palakurthi et al., 2001; Place et al., 2003; Perez-Ortiz et al., 2004; Rumi et al., 2004; Turturro et al., 2004) . Collectively, these data demonstrate that the high-affinity PPARg agonist, RS5444, is completely dependent upon PPARg to mediate inhibition of cell proliferation while the other two Tzds activate PPARg along with other unidentified cell proliferation inhibitory pathways in ATC cells. Indeed, PPARg independent inhibition of cell proliferation and induction of apoptosis have been attributed to Tzds such as troglitazone, rosiglitazone, and ciglitazone. Such mechanisms include inhibition of cyclin D3 and survivin in breast cancer (Lu et al., 2005) WAF1/CIP1 siRNA followed by treatment and DAPI staining. When p21 is silenced, combinatorial apoptotic effects are reduced. *Po0.05, when treatment is compared to control. **Po0.05, when combinatorial treatment is compared to paclitaxel alone. upregulation of GADD45 in breast cancer (Yin et al., 2004) , enhanced reactive oxygen species in gliomas (Perez-Ortiz et al., 2004) and ablation of cyclin D1 in breast cancer . In fact, the first generation Tzd, troglitazone, is also a vitamin E (atocopherol) analog and was originally synthesized in efforts to identify novel antioxidants (Fujiwara et al., 1998; Davies et al., 2002) . Thus, unlike troglitazone or rosiglitazone, RS5444 appears to be completely dependent upon functional PPARg for its anti-proliferative activity.
In vitro cell culture data suggested that PPARg could be a novel target for innovative therapy of thyroid carcinoma (Chung et al., 2002; Martelli et al., 2002; Hayashi et al., 2004) . Our study is the first to demonstrate that a PPARg ligand has antitumor activity against ATC in an animal model. For RS5444, the activity appeared to involve a cytostatic mechanism and not involve an apoptotic mechanism as shown in vivo and in vitro studies. Tzds, such as ciglitazone, have been recently shown to induce apoptosis (1 mM, PARP cleavage) in DRO cells and it appearred synergistic when combined with an RXR agonist (Klopper et al., 2004) . Whether induction of apoptosis is Tzd specific and/or PPARg-dependent remains to be tested.
Our data also indicated that RS5444 has antiangiogenic activity by decreasing CD31, a specific molecular marker of blood vessels. Antiangiogenic properties for Tzds and PPARg agonists have been described in preclinical models (Xin et al., 1999; Panigrahy et al., 2002; Margeli et al., 2003) and a clinical trial (Vogt et al., 2003) . These effects may be mediated through both PPARg-dependent and -independent pathways depending upon concentration of PPARg agonist and tumor cell type. Known angiogenesis inhibitory mechanisms for Tzds include directly inhibiting endothelial cell proliferation and migration as well as decreasing tumor-derived vascular endothelial growth factor (VEGF) production (Alarcon de la Lastra et al., 2004) . VEGF is a potent activator of angiogenesis and is secreted from many tumor types (Panigrahy et al., 2003) including ATC (Belletti et al., 1999; Sato, 2001; Xu et al., 2001) . Recently, a VEGF monoclonal antibody recognizing VEGF isoforms 121, 165, and 189 demonstrated antitumor activity against human ARO ATC tumors in a xenograft nude mouse model (Bauer et al., 2002) . As well, AEE788, a dual inhibitor of epidermal growth factor receptor (EGFR) and VEGF receptor (VEGFR) tyrosine kinases was able to inhibit the proliferation of ATC cell lines in vitro. Moreover, administration of AEE788 alone and in combination with paclitaxel to athymic nude mice inhibited the growth of ATC xenografts by 44 and 69%, respectively (Kim et al., 2005) . Thus this PPARg-specific Tzd, RS5444, possesses antiangiogenic activity in vivo and may further contribute to antitumor activity by attenuating VEGF signaling in ATC. This signaling pathway requires further examination to substantiate this speculation in ATC for RS5444.
Since RS5444 did not appear to induce cell death by apoptosis, we next examined other mechanisms related to growth inhibition such as cyclin kinase inhibitors (CKIs) that regulate cell cycle progression. The CKI, p21 WAF1/CIP1 , is known to complex with and inhibit cyclin dependent kinase 2 (CDK2)-cyclin E/A activity while this is less substantiated for cyclin Ds and CDK4/6 complexes (reviewed in Pei XH, 2005) . Cells expressing nuclear p21 WAF1/CIP1 were subsequently arrested in G 0 -G 1 phase of the cell cycle. p21 WAF1/CIP1 has been implicated as a modulator of PPARg-mediated inhibition of cell proliferation but this was correlative in nature (Chang and Szabo, 2000; Elnemr et al., 2000; Koga et al., 2001; Hong et al., 2004) . Our data indicated that in large part the antiproliferative activity of RS5444 is mediated through the upregulation of p21 WAF1/CIP1 in ATC tumors. Using siRNA technology, we provided a clear demonstration that p21 WAF1/CIP1 mediates ligandactivated PPARg-dependent inhibition of cell proliferation in human ATC cells. In the only other definitive study, Han et al. (2004) Kip1 is upregulated in response to ciglitazone and that p27 Kip1 mediates PPARg inhibition of cell proliferation and induction of apoptosis. In this study, p21 WAF1/CIP1 was not examined nor was p27
Kip1 silenced to demonstrate that p27
Kip1 mediates ciglitazone's growth inhibitory activity in ARO cells. Alternatively, it is conceivable that the two Tzds have different CKI specificities since ciglitazone induced apoptosis while RS5444 does not in ARO cells or as stated previously, it could be through PPARg-independent mechanisms.
To our knowledge, this is the first report to demonstrate that a PPARg agonist combined with a taxane enhances antitumor activity in vitro and in vivo. Moreover, it is the first demonstration that a thiazolidinedione enhances apoptosis in the presence of paclitaxel. We suspected and confirmed that both events were mediated via p21 WAF1/CIP1 . However, p21 WAF1/CIP1 was first shown to contribute to resistance of paclitaxel-induced apoptosis and was thought to do this by decreasing paclitaxel-induced G2-M arrest. The loss of normal p53 function (p53 transcriptionally upregulates p21 WAF1/CIP1 ) in fibroblast cells conferred sensitization to paclitaxel by increasing G 2 -M arrest and apoptosis (Wahl et al., 1996) . This was also shown in sarcoma and breast adenocarcinoma cell lines (Barboule et al., 1997; Li et al., 1999; Schmidt et al., 2000) . p21
WAF1/CIP1 has also been implicated in desensitizing cells to other chemotherapeutic agents such as cisplatin and nitrogen mustard (Fan et al., 1997) . Also in this report, the clonogenic survival of colon tumor cells, HCT-116, exposed to ionizing radiation, adriamycin, paclitaxel, or vincristine was not altered by p21 WAF1/CIP1 or p53 disruption suggesting that cell type and chemotherapeutic agent selection dictate the role of p21 WAF1/CIP1 in regulating responsiveness. In stark contrast, p21 WAF1/CIP1 was recently shown to be requisite for manumycin enhanced paclitaxel-induced apoptosis in a human ATC cell line, KAT4 (Yang et al., 2003) . In this study, overexpression of p21 WAF1/CIP1 alone did not induce apoptosis but when cells were treated with paclitaxel, apoptosis was enhanced. Overexpression of p21 WAF1/CIP1 led to enhanced activated caspase 3 levels in the presence of pactlitaxel in this study. To further support the role of p21 WAF1/CIP1 in enhancing apoptosis, a recent study examined two transgenic mouse models (Apc1638 þ /À and Muc2À/À) of intestinal tumorigenesis in which, p21 WAF1/CIP1 was inactivated . Muc2À/À mice developed tumors in the small and large intestine and the rectum, but in contrast to tumors in Apc1638 þ /À mice, increased expression or nuclear localization of b-catenin was not involved. Inactivation of p21 WAF1/CIP1 (p21 WAF1/CIP1À/À ) increased the frequency and size of intestinal tumors and also led to development of more invasive adenocarcinomas. Further, inactivation of p21
increased cell proliferation and decreased apoptosis in the mucosa of the small and large intestine. Thus, in these two mouse models, p21 WAF1/CIP1 modulated the formation of tumors whose initiation occurs through two different signaling mechanisms . In summary, expression levels and cellular localization may explain some findings that p21 WAF1/CIP1 antagonizes paclitaxel-induced apoptosis and inhibition of cell proliferation in certain tumor cells while enhancing these activities in others.
These collective data provide a rationale for examining combinatorial therapy of agents representative of a PPARg agonist and a taxane derivative in a clinical trial. Paclitaxel has demonstrated prolongation of life for ATC patients in a clinical trial and appears the standard of care with regards to chemotherapeutic intervention for patients diagnosed with ATC (Ain et al., 2000) . Aldred et al. (2003) described PPARg expression in thyroid cancer subtypes demonstrating that ATCs were positive by IHC in 9/14 cases and percentage-wise, PPARg expression was higher than any other thyroid cancer subtype. In their discussion, they noted that further studies of PPARg status in ATCs may provide insights into pathogenesis and management of ATC. We have also examined mRNA levels comparing six normal thyroid to that of six ATC tissues and found similar levels in all 12 tissues examined (DC t Normal Avg7s.d. is 21.1171.48 (n ¼ 6) and DC t Tumor Avg7s.d. is 21.0571.52 (n ¼ 6) with data being normalized to 18s RNA). It would appear logical to then compare paclitaxel therapy alone vs paclitaxel in combination with a PPARg agonist, especially a Tzd. Moreover, the toxicity profile of Tzds currently in use for treatment of type 2 diabetes (e.g. rosiglitazone, ciglitazone, and pioglitazone) is consistently benign with edema and risk of heart failure reported in 4-6% of patients compared with 1-2% of patients on placebo (reviewed in Yki-Jarvinen, 2004) . In addition, patients diagnosed with ATC are amenable to needle biopsy due to the surface location within the head and neck region. In a clinical trial, needle biopsy-derived tissue could be probed for PPARg expression and used as a marker for predicting responsiveness to a Tzd since mutations of PPARg have yet to be identified in ATC while the dominant negative PAX8/PPARg rearranged oncogene is common in follicular thyroid tumors (Kroll et al., 2000; Dwight et al., 2003; McIver et al., 2004) . Our data also indicated that an excellent molecular marker of response to Tzd therapy would be expression of p21 WAF1/ CIP1 , which could be examined after steady-state blood levels of Tzd are achieved in the patient.
Materials and methods

Chemicals
PPARg agonists RS5444 and troglitazone were kindly provided by (Sankyo Company, Ltd). GW9662 was purchased from Sigma-Aldrich (St Louis, MO) and rosiglitazone was from GlaxoSmithKline (Philadelphia, PA) or Mayo Clinic Pharmacy. Paclitaxel (Taxol s ; Bristol-Myers) was purchased from the Mayo Clinic Pharmacy and Sigma-Aldrich (St Louis, MO). For in vivo studies, paclitaxel was diluted in PBS at various concentrations and placebo was prepared with either 16.7 or 25% Cremophor EL (Sigma), 16.7 or 25% ethanol, and 66.6 or 50% PBS, respectively. RS5444 was added to rodent diet at 0.00025, 0.0025, and 0.025% as prepared by Research Diets, Inc. (New Brunswick, NJ). A 20 g mouse eats on average 4 g/day. Therefore, 0.00025% corresponds to 0.01 mg/day, 0.0025% corresponds to 0.1 mg/day and 0.025% diet is equivalent to 1 mg/day.
Cell culture DRO90-1 (DRO) and ARO81 (ARO) cells were derived from primary cultures of human anaplastic thyroid carcinoma tumors that were kindly provided by Dr GJ Juillard (University of California-Los Angeles, Los Angeles, CA). Cells were cultured in RPMI 1640 medium (Cellgro Herndon, VA) supplemented with 10% charcoal-stripped fetal bovine serum (Hyclone), nonessential amino acids, sodium pyruvate, and penicillin-streptomycin-amphotericin B at 371C in a humidified atmosphere with 5% CO 2 . Charcoal-stripped serum is used to remove any endogenous PPAR ligands.
siRNA transfection Cells were plated 7.5 Â 10 4 cells/ml in either six-well or 12-well plates and allowed to adhere overnight. Cells were transfected for 72 h with 2 to 5 mg of either scrambled, p21 WAF1/CIP1 or PPARg-specific siRNA duplexes (Qiagen Valencia, CA) using RNAiFect reagent (Qiagen). The DNA target sequence for PPARg used was 5 0 -GCCCTTCACTACTGTTGAC-3 0 .
Growth curves
Cells were plated in 12-well culture plates in triplicate for each condition at an initial concentration of 2 Â 10 4 cells/well. After overnight incubation, cells were treated with either RS5444, rosiglitazone, troglitazone, GW9662, or paclitaxel diluted in DMSO (Sigma) at concentrations indicated in figure legends. All cells received identical volumes of DMSO and were exposed to each drug for 6 days with medium and drug changed every 48 h. After 6 days, cells were washed with PBS (Cellgro), trypsinized and counted by Beckman Coulter Counter.
Luciferase reporter gene analysis Specific activation of PPRE3-tk-luc (a gift of R Evans, Salk Institute, La Jolla, CA) by RS5444, rosiglitazone, and troglitazone was demonstrated by dual luciferase assay. Cells were plated in six-well culture plates in triplicate for each condition at an initial concentration of 2 Â 10 5 cells/well. After overnight incubation, cells were transfected with PPRE/luc and CMV/renilla luciferase plasmid using Lipofectamine 2000 (Invitrogen). After 24 h, cells were treated with PPARg agonists at various concentrations diluted in DMSO. After 24 h of drug treatments, cells were washed with PBS, lysed in lysis buffer and luciferase activity was measured with Promega's Dual Luciferase assay kit with a luminometer. The enzyme activity was normalized for efficiency of transfection on the basis of renilla activity levels and reported as relative light units (RLU).
Immunostaining Cells were plated on coverslips in six-well culture plates at 1 Â 10 5 cells/well and were allowed to adhere overnight. Cells were then fixed with 2% Paraformaldehyde followed by permeabilization with ice-cold 100% methanol. Tissues were quenched in hydrogen peroxide and blocked with Diluent containing background reducing components (Dako) and probed with either PPARg1, 2 antibody (Biomol), PCNA (Dako) or CD31 (Santa Cruz) in Diluent at room temperature. Slides were washed with PBS þ 0.05% Tween followed by 45 min incubation in Diluent with either antirabbit/mouse/ goat horseradish peroxidase (Sigma) or FITC conjugate (Jackson Labs). Slides were washed again with PBS þ 0.05% Tween. Bound HRP antibody was detected with buffered DAB chromogen (Dako). Negative controls was performed by incubating slides in the absence of primary antibody. For PCNA and CD31 IHC, Day 35 DRO tumors were excised and processed for IHC staining. Quantification of PCNA-positive cells for proliferation density and quantification of microvessels (CD31 positive) for the assessment of microvasculature in tumor tissues was calculated using Image-Pro Plus. For apoptosis studies, slides were incubated in DAPI (Dako) followed by washing with PBS þ 0.05% Tween. The TdTmediated dUTP nick end labeling (TUNEL) assay was carried out according to the manufacturer's protocol (Calbiochem). Apoptosis was characterized by positive DAPI or TUNEL staining and three microscopic fields in each group were used to calculate the percentage of positive cells. All slides were analysed using an Olympus microscope either with white light or fluorescence.
Cell lysis and western blot analysis Cells were plated in 10 cm plates for each condition at an initial concentration of 3 Â 10 5 cells/plate. Cells were treated with 10 nM RS5444 and all cells received identical volumes of DMSO. For each condition, cells were collected including any floating cells and lysed in RIPA buffer containing 50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.1% SDS, 0.5% Deoxycholate, 1% NP40 and protease inhibitor cocktail (Roche) followed by centrifugation. Excised tumor tissues were lysed in 50 mM Tris pH 8.0 þ 1% SDS. The collected supernatant was measured for protein concentration using Pierce's BCA assay. Protein (25 mg) was loaded on SDS-Page gels (Invitrogen) and then transferred to Immobilon-P membranes. The membranes were hybridized with antibodies (Biomol, Cell Signal, Sigma) to the indicated proteins overnight at 41C followed by their speciesspecific horseradish peroxidase IgG (Jackson labs) at room temperature. Detection was performed using enhanced chemoluminescence kit (Amersham).
Soft agar assays
Soft agar assays for anchorage-independent growth were performed on DRO and ARO cells. Each 60 mm plate was first layered with 0.75% agar diluted with 10% FBSsupplemented RPMI medium complete with additives. The cell layer was then prepared as previously stated with 10 3 cells per plate. Plates were maintained at 371C under 5% CO 2 for 2 weeks. Colonies visible to the naked eye were counted by hand.
Xenograft studies
Suspensions of 1 Â 10 6 /0.1 ml DRO or ARO cells in RPMI medium were injected subcutaneously in one flank of 3-4 week athymic female nude mice (Harlan). Mice were changed to specialized diets either 1 week prior or 1 week after tumor implantation and randomly assigned to experimental or control groups with 10 mice per group. Diets consisted either placebo, 0.00025%, 0.0025%, or 0.025% RS5444 formulated into the diet (Research Diets). Mice weighed between 20-25 g and consume on average 4 g of food per day. For combinatorial in vivo studies either placebo, 10 mg/kg or 15 mg/kg paclitaxel was injected i.p. twice weekly. Tumors were measured every 3-4 days for 35 days with calipers and tumor volumes were calculated by the formula: 0.5236(a Â b Â c), where a is the shortest diameter, b is the diameter perpendicular to a and c is the diameter height.
Real-time PCR
Applied Biosystems' assays-on-demand 20 Â assay mix of primers and TaqMan MGB probes (FAMt dye-labeled) for PPARg (Hs00234592_m1) and 18S rRNA (VICt-dye labeled probe) TaqMan s assay reagent (P/N 4319413E) for internal control were used for real-time PCR measurements. All absolute values of the slope of log input amount verses DC t is o0.1. Separate tubes (singleplex) for one-step RT-PCR was performed with 10 ng RNA for both target genes and endogenous controls using TaqMan one-step RT-PCR master mix reagent kit (Applied Biosystems). The cycling parameters for one-step RT-PCR were: reverse transcription 481C for 30 min, AmpliTaq activation 95C for 10 min, denaturation 95C for 15 s and annealing/extension 601C for 1 min (repeat 40 times) on ABI7000. Duplicate C t values are analysed with Microsoft excel using the comparative C t (DDC t ) method as described by the manufacturer (Applied Biosystems). The amount of target ð2 ÀDDCt Þ was obtained by normalizing to an endogenous reference (18s mRNA) and relative to a calibrator (normal tissue).
Statistical analysis
Data are presented as the mean7s.d. unless otherwise specified. Comparisons of treatment groups was analysed by two-tailed paired or unpaired Student's t-test, as appropriate based upon F tests. Po0.05 was considered statistically significant.
Abbreviations
PPARg, Peroxisome proliferators-activated receptor gamma; ATC, anaplastic thyroid carcinoma; Tzd, thiazolidinedione; ICC, immunocytochemistry; IHC, immunohistochemistry.
